Research Analysts Offer Predictions for GPCR Q1 Earnings

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) – Research analysts at HC Wainwright lowered their Q1 2026 earnings estimates for Structure Therapeutics in a report released on Monday, March 2nd. HC Wainwright analyst A. Ghosh now anticipates that the company will post earnings of ($0.43) per share for the quarter, down from their previous forecast of ($0.30). HC Wainwright has a “Buy” rating and a $114.00 price target on the stock. The consensus estimate for Structure Therapeutics’ current full-year earnings is ($0.82) per share. HC Wainwright also issued estimates for Structure Therapeutics’ Q2 2026 earnings at ($0.43) EPS, Q3 2026 earnings at ($0.43) EPS, Q4 2026 earnings at ($0.44) EPS, FY2026 earnings at ($1.72) EPS, FY2027 earnings at ($2.34) EPS, FY2028 earnings at ($2.45) EPS, FY2029 earnings at ($2.54) EPS and FY2030 earnings at ($2.28) EPS.

Structure Therapeutics (NASDAQ:GPCR) last released its earnings results on Thursday, February 26th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.14).

Several other equities research analysts also recently commented on the company. Wall Street Zen raised Structure Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, February 28th. Morgan Stanley lifted their price target on Structure Therapeutics from $120.00 to $125.00 and gave the stock an “overweight” rating in a research report on Friday, December 12th. BMO Capital Markets reiterated an “outperform” rating on shares of Structure Therapeutics in a research note on Tuesday, January 6th. Weiss Ratings restated a “sell (d-)” rating on shares of Structure Therapeutics in a research note on Thursday, January 22nd. Finally, Stifel Nicolaus lifted their target price on shares of Structure Therapeutics from $50.00 to $90.00 and gave the stock a “buy” rating in a report on Monday, December 8th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, Structure Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $107.90.

Structure Therapeutics Stock Down 5.4%

Structure Therapeutics stock opened at $59.70 on Thursday. Structure Therapeutics has a twelve month low of $13.22 and a twelve month high of $94.90. The company has a market capitalization of $4.22 billion, a P/E ratio of -75.57 and a beta of -1.80. The stock’s 50 day moving average is $74.89 and its 200 day moving average is $47.74.

Hedge Funds Weigh In On Structure Therapeutics

Several institutional investors have recently made changes to their positions in GPCR. CWM LLC raised its stake in shares of Structure Therapeutics by 35.2% in the fourth quarter. CWM LLC now owns 480 shares of the company’s stock valued at $33,000 after acquiring an additional 125 shares during the period. EverSource Wealth Advisors LLC boosted its stake in shares of Structure Therapeutics by 530.0% during the 3rd quarter. EverSource Wealth Advisors LLC now owns 1,071 shares of the company’s stock worth $30,000 after purchasing an additional 901 shares during the period. State of Wyoming bought a new position in Structure Therapeutics during the 2nd quarter valued at about $28,000. Police & Firemen s Retirement System of New Jersey purchased a new stake in Structure Therapeutics in the 4th quarter worth about $127,000. Finally, Assetmark Inc. raised its position in Structure Therapeutics by 39.9% in the 2nd quarter. Assetmark Inc. now owns 2,877 shares of the company’s stock worth $60,000 after purchasing an additional 820 shares during the period. Institutional investors own 91.78% of the company’s stock.

Key Structure Therapeutics News

Here are the key news stories impacting Structure Therapeutics this week:

• Positive Sentiment: HC Wainwright kept a Buy rating and a $114 price target, signaling continued conviction in the company’s longer-term upside despite the model cuts. Structure Therapeutics (NASDAQ:GPCR) Price Target Raised to $114.00
• Neutral Sentiment: HC Wainwright published comprehensive model revisions (quarterly and multi-year EPS updates) rather than company guidance changes; the current consensus full‑year EPS remains around ($0.82) per share.
• Negative Sentiment: The analyst materially lowered near‑term quarterly forecasts to roughly ($0.43)–($0.44) per quarter for 2026 (from prior ~($0.30) estimates) and pushed FY2026–FY2030 EPS substantially deeper (e.g., FY2026 to ($1.72) from ($1.20); FY2027 to ($2.34) from ($1.70); FY2028 to ($2.45) from ($1.78); FY2029 to ($2.54) from ($1.87); FY2030 to ($2.28) from ($1.74)). These larger loss projections increase near-term execution and financing risk and are the likely trigger for the stock’s downward move today.

About Structure Therapeutics

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.